Publication date: Mar 02, 2019
Clinical trial at UB to test new treatment for Parkinson’s disease dementia One of the challenging characteristics of Parkinson’s disease dementia is ‘imposter syndrome,’ where patients believe that a loved one has been replaced by an identical imposter.
Kinga Szigeti, MD, PhD, Associate professor of neurology and director of the Alzheimer’s Disease and Memory Disorders Center -The neuropsychiatric symptoms can make this kind of dementia much more challenging for families to deal with than Alzheimer’s disease. “
BUFFALO, N. Y. – After Alzheimer’s disease, Lewy body dementia and related Parkinson’s disease dementia (PDD) are some of the most common types of dementia affecting older adults, but they are severely understudied.
Interested patients will be seen at UBMD Neurology, where Szigeti is director of its Alzheimer’s Disease and Memory Disorders Center.
-The neuropsychiatric symptoms can make this kind of dementia much more challenging for families to deal with than Alzheimer’s disease,” Szigeti said.
But now, Western New York patients have an opportunity to participate in the first clinical trial to test a medication for Lewy body dementia at the Jacobs School.
|disease||MESH||Lewy body dementia|
|disease||DOID||Lewy body dementia|
- Lewy Body Dementias.
- Cholinesterase inhibitors and memantine for Parkinson’s disease dementia and Lewy body dementia: A meta-analysis.
- Nucleic Acid-Based Therapeutics for Parkinson’s Disease.